Influence of combined treatment with mianserin and simvastatin on selected biochemical serum parameters of liver and kidney function in rats
DOI:
https://doi.org/10.12923/j.2084-980X/26.3/a.04Słowa kluczowe:
mianserin, simvastatin, biochemical liver and kidney parameters, ratsAbstrakt
The aim of the present study was to assess the impact of combined 14-day treatment with mianserin (10 mg/kg) and simvastatin (1 or 10 mg/kg) on selected biochemical liver and kidney parameters in rats (AST and ALT activities and the concentrations of AFP, total protein, urea, creatinine and ß2-M). The results showed the increase in both transaminases activities, creatinine concentration and the decrease of AFP, total protein and ß2-M concentrations. The results indicate that 14-day combined administration of mianserin with simvastatin negatively affects the liver functioning. The observed changes in kidney biochemical parameters may suggest a risk of renal dysfunction during long-term combined treatment with these drugs.
Bibliografia
1. Agarwal R.: Effects of statins on renal function. Am. J. Cardiol., 97, 748, 2006.
2. Almuti K. et al.: Effects of statins beyond lipid lowering: Potential for clinical benefits. Int. J. Cardiol., 109, 7, 2006.
3. Bays H.: Statin Safety: An Overview and Assessment of the Data - 2005. Am. J. Cardiol., 97, 6C, 2006.
4. Chalasani N. et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 126, 1287, 2004.
5. Charles E. C. et al.: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am. J. Med., 118, 618, 2005.
6. Cohen D.E. et al.: An Assessment of Statin Safety by Hepatologists. Am. J. Cardiol., 97 (1), S77, 2006.
7. Degreef L.E. et al.: The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. Eur. J. Intern. Med., 21, 293, 2010.
8. Denus S. et al.: Statins and liver toxicity: a meta-analysis. Pharmacotherapy, 24, 584, 2004.
9. Girard M. et al.: Mianserin side-effects. J Lancet, 336, 1439, 1990.
10. Herbet M. et al.: Evaluation of selected biochemical parameters in the serum of rats pretreated with simvastatin, doxepin or their combination. Ann. Umcs Sect. DDD, 24, 107, 2011.
11. Herbet M. et al.: The influence of combined treatment of simvastatin and amitriptyline on some biochemical parameters in rat serum. Ann. Umcs Sect. DDD, 23, 121, 2010.
12. Herman R.J.: Drug interactions and the statins. CMAJ, 16, 1281, 1999.
13. Jacobson T.A.: Statin Safety: Lessons from New Drug Applications for Marketed Statins. Am. J. Cardiol., 97, 44, 2006.
14. Karnik N.S., Maldonado J. R.: Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics, 46, 565, 2005.
15. Kasiske B.L. et al.: An Assessment of Statin Safety by Nephrologists. Am J Cardiol, 97(8A): 82C, 2006.
16. Kassimatis T.I., Konstantinopoulos P.A.: The role of statins in chronic kidney disease (CKD): Friend or foe? Pharmacol. Ther., 122, 312, 2009.
17. Musselman D.L. et al.: The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch. Gen. Psychiatry, 55, 580, 1998.
18. Paoletti R. et al.: Pharmacological interactions of statins. Atherosclerosis, 3, 35, 2002.
19. Rajewska J., Rajewski A.: Mianserin therapy of depressive patients with coexisting cardiovascular diseases. Eur Neuropsychopharmacol, Vol 6, Suppl 4, S4-87, 1996.
20. Roose S.P. et al.: Pharmacologic treatment of depression in patients with heart disease. Psychosom Med., 67, 54, 2005.
21. Rudnik-Szałaj I.. et al.: Zastosowanie mianseryny w leczeniu depresji. Psychiatria Polska, 34, 71, 2000.
22. Rybakowski J.K. et al.: One-year course of the first vs multiple episodes of depression – Polish naturalistic study. Eur. Psychiatry, 19, 258, 2004.
23. Skrabal M.Z. et al.: Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med. J., 96, 1034, 2003.
24. Smith C.C. et al.: Screening for Statin-Related Toxicity: The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting. Arch. Intern. Med., 163, 688, 2003.
25. Talbert R.L.: Safety issues with statin therapy. J Am Pharm Assoc, 46, 479, 2006.
26. Tolman K.G.: The liver and lovastatin. ACC Curr J Rev, 89, 1374, 2002.
27. Tousoulis D. et al.: Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol, 115, 144, 2007.
28. Vikram K. et al.: Major Depression with Ischemic Heart Disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry, 52, 418, 2002.
29. Wakeling A.: Efficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad. Med. J., 59, 229, 1983.
30. Wang C.Y. et al.: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 14, 37, 2008.
31. Wille S.M. et al.: Relevant issues in the monitoring and the toxicology of antidepressants. Crit. Rev. Clin. Lab. Sc.i, 45, 25, 2008.
Pobrania
Opublikowane
Numer
Dział
Licencja
Prawa autorskie (c) 2013 Autorzy
Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
